Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates

Journal of Virology

Volumn 84, Issue 19, 2010, Pages 10386-10394

  Geisbert, Thomas W ^a,e   Bailey, Michael ^b   Geisbert, Joan B ^a   Asiedu, Clement ^b   Roederer, Mario ^b   Grazia Pau, Maria ^d   Custers, Jerome ^d   Jahrling, Peter ^c   Goudsmit, Jaap ^d   Koup, Richard ^b   Sullivan, Nancy J ^b  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d CRUCELL HOLLAND BV   (Netherlands)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DNA VACCINE; GAMMA INTERFERON; GLYCOPROTEIN; INTERLEUKIN 2; PLASMID DNA; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; VIRUS PROTEIN; VIRUS VACCINE;

ADENOVIRUS 5; ANGOLA; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DNA VECTOR; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; INOCULATION; MARBURG VIRUS; NONHUMAN; PHENOTYPE; PRIMATE; PRIORITY JOURNAL; VACCINATION; VIRUS INFECTION; ANIMAL; ANIMAL MODEL; CELLULAR IMMUNITY; COMPARATIVE STUDY; GENE VECTOR; GENETICS; IMMUNIZATION; IMMUNOLOGY; MACACA FASCICULARIS; MARBURG VIRUS DISEASE; METABOLISM; VIRUS GENE;

ADENOVIRIDAE; LAKE VICTORIA MARBURGVIRUS; PRIMATES;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; GENES, VIRAL; GENETIC VECTORS; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; MACACA FASCICULARIS; MARBURG VIRUS DISEASE; MARBURGVIRUS; MODELS, ANIMAL; VACCINES, DNA; VIRAL PROTEINS; VIRAL VACCINES;

EID: 77956831573     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00594-10     Document Type: Article

References (28)

1. Barouch, D. H., Z. Y. Yang, W. P. Kong, B. Korioth-Schmitz, S. M. Sumida, D. M. Truitt, M. G. Kishko, J. C. Arthur, A. Miura, J. R. Mascola, N. L. Letvin, and G. J. Nabel. 2005. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J. Virol. 79:8828-8834.
2. Betts, M. R., M. C. Nason, S. M. West, S. C. De Rosa, S. A. Migueles, J. Abraham, M. M. Lederman, J. M. Benito, P. A. Goepfert, M. Connors, M. Roederer, and R. A. Koup. 2006. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107:4781-4789.
3. Casazza, J. P., M. R. Betts, D. A. Price, M. L. Precopio, L. E. Ruff, J. M. Brenchley, B. J. Hill, M. Roederer, D. C. Douek, and R. A. Koup. 2006. Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation. J. Exp. Med. 203:2865-2877.
4. Darrah, P. A., D. T. Patel, P. M. De Luca, R. W. Lindsay, D. F. Davey, B. J. Flynn, S. T. Hoff, P. Andersen, S. G. Reed, S. L. Morris, M. Roederer, and R. A. Seder. 2007. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13:843-850.
5. De Rosa, S. C., F. X. Lu, J. Yu, S. P. Perfetto, J. Falloon, S. Moser, T. G. Evans, R. Koup, C. J. Miller, and M. Roederer. 2004. Vaccination in humans generates broad T cell cytokine responses. J. Immunol. 173:5372-5380.
6. Geisbert, T. W., K. M. Daddario-DiCaprio, J. B. Geisbert, H. A. Young, P. Formenty, E. A. Fritz, T. Larsen, and L. E. Hensley. 2007. Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2. J. Infect. Dis. 196(Suppl. 2):S372-S381.
7. Geisbert, T. W., L. E. Hensley, T. R. Gibb, K. E. Steele, N. K. Jaax, and P. B. Jahrling. 2000. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab. Invest. 80:171-186.
8. Hevey, M., D. Negley, P. Pushko, J. Smith, and A. Schmaljohn. 1998. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 251:28-37. (Pubitemid 28527716)
9. Johnson, E. D., B. K. Johnson, D. Silverstein, P. Tukei, T. W. Geisbert, A. N. Sanchez, and P. B. Jahrling. 1996. Characterization of a new Marburg virus isolated from a 1987 fatal case in Kenya. Arch. Virol. Suppl. 11:101-114.
10. Jones, S. M., H. Feldmann, U. Stroher, J. B. Geisbert, L. Fernando, A. Grolla, H. D. Klenk, N. J. Sullivan, V. E. Volchkov, E. A. Fritz, K. M. Daddario, L. E. Hensley, P. B. Jahrling, and T. W. Geisbert. 2005. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11:786-790.
11. Kissling, R. E., F. A. Murphy, and B. E. Henderson. 1970. Marburg virus. Ann. N. Y. Acad. Sci. 174:932-945.
12. Kutzler, M. A., and D. B. Weiner. 2008. DNA vaccines: ready for prime time? Nat. Rev. Genet. 9:776-788.
13. Lu, S., S. Wang, and J. M. Grimes-Serrano. 2008. Current progress of DNA vaccine studies in humans. Expert Rev. Vaccines 7:175-191.
14. Mahanty, S., and M. Bray. 2004. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect. Dis. 4:487-498.
15. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC.
16. Perfetto, S. P., P. K. Chattopadhyay, L. Lamoreaux, R. Nguyen, D. Ambrozak, R. A. Koup, and M. Roederer. 2006. Amine reactive dyes: an effective tool to discriminate live and dead cells in polychromatic flow cytometry. J. Immunol. Methods 313:199-208.
17. Precopio, M. L., M. R. Betts, J. Parrino, D. A. Price, E. Gostick, D. R. Ambrozak, T. E. Asher, D. C. Douek, A. Harari, G. Pantaleo, R. Bailer, B. S. Graham, M. Roederer, and R. A. Koup. 2007. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J. Exp. Med. 204:1405-1416.
18. Riemenschneider, J., A. Garrison, J. Geisbert, P. Jahrling, M. Hevey, D. Negley, A. Schmaljohn, J. Lee, M. K. Hart, L. Vanderzanden, D. Custer, M. Bray, A. Ruff, B. Ivins, A. Bassett, C. Rossi, and C. Schmaljohn. 2003. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine 21:4071-4080.
19. Santra, S., M. S. Seaman, L. Xu, D. H. Barouch, C. I. Lord, M. A. Lifton, D. A. Gorgone, K. R. Beaudry, K. Svehla, B. Welcher, B. K. Chakrabarti, Y. Huang, Z. Y. Yang, J. R. Mascola, G. J. Nabel, and N. L. Letvin. 2005. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J. Virol. 79:6516-6522.
20. Santra, S., Y. Sun, B. Korioth-Schmitz, J. Fitzgerald, C. Charbonneau, G. Santos, M. S. Seaman, S. J. Ratcliffe, D. C. Montefiori, G. J. Nabel, H. C. Ertl, and N. L. Letvin. 2009. Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. Vaccine 27:5837-5845.
21. Seder, R. A., P. A. Darrah, and M. Roederer. 2008. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8:247-258.
22. Sullivan, N. J., T. W. Geisbert, J. B. Geisbert, L. Xu, Z. Y. Yang, M. Roederer, R. A. Koup, P. B. Jahrling, and G. J. Nabel. 2003. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424:681-684.
23. Sullivan, N. J., J. E. Martin, B. S. Graham, and G. J. Nabel. 2009. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat. Rev. Microbiol. 7:393-400.
24. Sullivan, N. J., A. Sanchez, P. E. Rollin, Z. Y. Yang, and G. J. Nabel. 2000. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408:605-609.
25. Swenson, D. L., D. Wang, M. Luo, K. L. Warfield, J. Woraratanadharm, D. H. Holman, J. Y. Dong, and W. D. Pratt. 2008. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin. Vaccine Immunol. 15:460-467.
26. Swenson, D. L., K. L. Warfield, T. Larsen, D. A. Alves, S. S. Coberley, and S. Bavari. 2008. Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Expert Rev. Vaccines 7:417-429.
27. Towner, J. S., M. L. Khristova, T. K. Sealy, M. J. Vincent, B. R. Erickson, D. A. Bawiec, A. L. Hartman, J. A. Comer, S. R. Zaki, U. Stroher, F. Gomes da Silva, F. del Castillo, P. E. Rollin, T. G. Ksiazek, and S. T. Nichol. 2006. Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. J. Virol. 80:6497-6516.
28. Uchijima, M., A. Yoshida, T. Nagata, and Y. Koide. 1998. Optimization of codon usage of plasmid DNA vaccine is required for the effective MHC class I-restricted T cell responses against an intracellular bacterium. J. Immunol. 161:5594-5599. (Pubitemid 28519124)